Guardant Health (NASDAQ:GH) Price Target Raised to $180.00

Guardant Health (NASDAQ:GH) had its target price increased by Leerink Partners from $170.00 to $180.00 in a report published on Friday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, January 22nd. Barclays reiterated an “overweight” rating and issued a $130.00 price target on shares of Guardant Health in a research report on Friday. Evercore set a $110.00 price target on shares of Guardant Health in a research note on Friday. UBS Group restated a “buy” rating and issued a $175.00 price objective on shares of Guardant Health in a research note on Friday, January 30th. Finally, BTIG Research upped their target price on shares of Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a report on Friday. Twenty-one analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $117.43.

Guardant Health Price Performance

NASDAQ GH opened at $103.10 on Friday. The company has a fifty day moving average of $106.69 and a two-hundred day moving average of $86.51. The company has a market capitalization of $13.52 billion, a PE ratio of -31.15 and a beta of 1.63. Guardant Health has a 1 year low of $34.88 and a 1 year high of $120.74.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. The business’s revenue was up 39.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. On average, research analysts expect that Guardant Health will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In other news, CEO Helmy Eltoukhy sold 90,565 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the sale, the chief executive officer owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. This trade represents a 4.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amirali Talasaz sold 100,000 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.05, for a total transaction of $10,505,000.00. Following the transaction, the chief executive officer owned 168,223 shares in the company, valued at approximately $17,671,826.15. This trade represents a 37.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 434,511 shares of company stock worth $45,580,887 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Guardant Health

Institutional investors have recently added to or reduced their stakes in the stock. Emerald Advisers LLC grew its stake in shares of Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new position in shares of Guardant Health in the 3rd quarter worth $1,554,000. Edgestream Partners L.P. boosted its holdings in Guardant Health by 147.3% in the second quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock valued at $2,629,000 after acquiring an additional 30,094 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its holdings in Guardant Health by 54.4% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after acquiring an additional 106,263 shares during the last quarter. Finally, Yorktown Management & Research Co Inc purchased a new stake in Guardant Health during the second quarter valued at about $289,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Key Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Multiple brokerages raised price targets and maintained buy/overweight ratings (Leerink to $180, JPMorgan to $130, Wells Fargo to $125, BTIG to $145, Canaccord to $135), signaling analyst confidence in upside from current levels. Analyst Raises Coverage
• Positive Sentiment: Q4 revenue beat and strong growth: Guardant reported $281.3M in Q4 revenue, +39% YoY and above consensus; management issued FY2026 revenue guidance around $1.3B, above Street expectations — a growth signal for core oncology testing. Press Release
• Positive Sentiment: Research coverage expansion: Robert W. Baird initiated coverage, which can broaden institutional interest and trading liquidity. Coverage Start
• Neutral Sentiment: Conference call and transcript available — provides detail on cadence of test volume, reimbursement progress and product roadmap; useful for digging into guidance assumptions. Earnings Transcript
• Neutral Sentiment: Market materials (slide deck, press release) posted for investors to verify segment trends and margin assumptions. Slide Deck / Press Release
• Neutral Sentiment: Short-interest data flagged a “significant increase” entry but shows 0 shares / NaN in the feed — the published data appears inconsistent, so short-interest impact is unclear. Short Interest Note
• Negative Sentiment: EPS miss: GAAP loss of ($0.50) vs. consensus (~($0.43)), which disappointed some investors despite revenue upside and may have pressured the stock near the close. Earnings Reaction
• Negative Sentiment: Management left EPS guidance effectively blank in the release (revenue guidance given but no numeric EPS target), which can create uncertainty around near-term profitability expectations. Guidance Details

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.